183 related articles for article (PubMed ID: 30252484)
1. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O
Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Parrish KE; Cen L; Murray J; Calligaris D; Kizilbash S; Mittapalli RK; Carlson BL; Schroeder MA; Sludden J; Boddy AV; Agar NY; Curtin NJ; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2015 Dec; 14(12):2735-43. PubMed ID: 26438157
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
8. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
Lin F; Buil L; Sherris D; Beijnen JH; van Tellingen O
Int J Cancer; 2013 Sep; 133(5):1222-33. PubMed ID: 23436212
[TBL] [Abstract][Full Text] [Related]
10. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
Li Y; Wu Q; Li C; Liu L; Du K; Shen J; Wu Y; Zhao X; Zhao M; Bao L; Gao J; Keep RF; Xiang J
PLoS One; 2016; 11(6):e0157576. PubMed ID: 27300692
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
[TBL] [Abstract][Full Text] [Related]
12. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Oplustil O'Connor L; Rulten SL; Cranston AN; Odedra R; Brown H; Jaspers JE; Jones L; Knights C; Evers B; Ting A; Bradbury RH; Pajic M; Rottenberg S; Jonkers J; Rudge D; Martin NM; Caldecott KW; Lau A; O'Connor MJ
Cancer Res; 2016 Oct; 76(20):6084-6094. PubMed ID: 27550455
[TBL] [Abstract][Full Text] [Related]
13. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Minocha M; Khurana V; Qin B; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
[TBL] [Abstract][Full Text] [Related]
14. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib.
Song YK; Park JE; Oh Y; Hyung S; Jeong YS; Kim MS; Lee W; Chung SJ
J Pharmacol Exp Ther; 2019 Jan; 368(1):79-87. PubMed ID: 30396915
[TBL] [Abstract][Full Text] [Related]
16. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
[No Abstract] [Full Text] [Related]
18. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
Martínez-Chávez A; Loos NHC; Lebre MC; Tibben MM; Rosing H; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():105954. PubMed ID: 34700018
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of an AZD2461 [
Reilly SW; Puentes LN; Schmitz A; Hsieh CJ; Weng CC; Hou C; Li S; Kuo YM; Padakanti P; Lee H; Riad AA; Makvandi M; Mach RH
Bioorg Chem; 2019 Mar; 83():242-249. PubMed ID: 30390553
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
